Clinical Trial Update: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ianalumab versus placebo in addition to eltrombopag for adults with primary immune thrombocytopenia. The trial is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)
• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: ACTIVE_NOT_RECRUITING